FMP
Cellectar Biosciences, Inc.
CLRB
NASDAQ
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
0.312 USD
0.0096 (3.07%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Revenue %
-
-
-
-
-
-
-
-
-
Ebitda
-15.15M
-23.98M
-28.67M
-38.77M
-51.78M
-
-
-
-
-
Ebitda %
100
100
100
100
100
100
100
100
100
Ebit
-15.36M
-24.21M
-28.9M
-38.96M
-51.78M
-
-
-
-
-
Ebit %
100
100
100
100
100
100
100
100
100
Depreciation
207.93k
227.64k
238.87k
192.38k
-
-
-
-
-
-
Depreciation %
100
100
100
100
100
100
100
100
100
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
57.17M
35.7M
19.87M
9.56M
23.29M
-
-
-
-
-
Total Cash %
100
100
100
100
100
100
100
100
100
Receivables
-
-
-
-
-
-
-
-
-
-
Receivables %
100
100
100
100
100
100
100
100
100
Inventories
-
-
-
-
-
-
-
-
-
-
Inventories %
100
100
100
100
100
100
100
100
100
Payable
1.43M
1.42M
2.56M
5.62M
611k
-
-
-
-
-
Payable %
100
100
100
100
100
100
100
100
100
Cap Ex
-62.35k
-141.36k
-225.97k
-864.04k
-104.19k
-
-
-
-
-
Cap Ex %
100
100
100
100
100
-
-
-
-
Weighted Average Cost Of Capital
Price
0.31
Beta
Diluted Shares Outstanding
37.14M
Costof Debt
4
Tax Rate
After Tax Cost Of Debt
4
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
494k
Total Equity
11.6M
Total Capital
12.1M
Debt Weighting
4.08
Equity Weighting
95.92
Wacc
7.02
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
-
-
-
-
-
-
-
-
-
-
Ebitda
-15.15M
-23.98M
-28.67M
-38.77M
-51.78M
-
-
-
-
-
Ebit
-15.36M
-24.21M
-28.9M
-38.96M
-51.78M
-
-
-
-
-
Tax Rate
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
-0.15
Ebiat
-15.01M
-24.06M
-28.84M
-38.9M
-51.85M
-
-
-
-
-
Depreciation
207.93k
227.64k
238.87k
192.38k
-
-
-
-
-
-
Receivables
-
-
-
-
-
-
-
-
-
-
Inventories
-
-
-
-
-
-
-
-
-
-
Payable
1.43M
1.42M
2.56M
5.62M
611k
-
-
-
-
-
Cap Ex
-62.35k
-141.36k
-225.97k
-864.04k
-104.19k
-
-
-
-
-
Ufcf
-13.44M
-23.98M
-27.69M
-36.51M
-56.97M
-611k
-
-
-
-
Wacc
7.02
7.02
7.02
7.02
7.02
Pv Ufcf
-570.92k
0
0
0
0
Sum Pv Ufcf
-570.9k
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
7.02
Free Cash Flow T1
0
Terminal Value
0
Present Terminal Value
0
Intrinsic Value
Enterprise Value
-570.9k
Net Debt
-22.79M
Equity Value
22.22M
Diluted Shares Outstanding
37.14M
Equity Value Per Share
0.6
Projected DCF
0.59832 0.478%
